Trial · NCT02674854

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT02674854, Phase 3, Completed, Aerie Pharmaceuticals; results first posted 2019-05-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension. Trials, record NCT02674854. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02674854

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
NCT number: NCT02674854
Status: Completed
Phases: Phase 3
Enrollment: 750 participants, actual
Lead sponsor: Aerie Pharmaceuticals
Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
First posted: 2016-02-05
Last updated: 2019-05-21
Results first posted: 2019-05-01

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Intraocular Pressure (IOP)	3 months	Mean intraocular pressure(IOP) at 08:00, 10:00 and 16:00 hours, at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Intraocular Pressure (IOP)	3 months	Intent to treat (ITT) population with Monte Carlo Markov Chain (MCMC) imputation	mmHg	MEAN

Source ClinicalTrials.gov

Results by group36

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution	Day 1, 0800 hours	24.69	Standard Deviation 3.422	mmHg
Intraocular Pressure (IOP)	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	Day 1, 0800 hours	24.66	Standard Deviation 3.148	mmHg
Intraocular Pressure (IOP)	Latanoprost Ophthalmic Solution 0.005%	Day 1, 0800 hours	24.75	Standard Deviation 3.240	mmHg
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution	Day 1, 1000 hours	23.33	Standard Deviation 3.399	mmHg
Intraocular Pressure (IOP)	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	Day 1, 1000 hours	23.40	Standard Deviation 3.538	mmHg
Intraocular Pressure (IOP)	Latanoprost Ophthalmic Solution 0.005%	Day 1, 1000 hours	23.23	Standard Deviation 3.339	mmHg
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution	Day 1, 1600 hours	22.37	Standard Deviation 3.492	mmHg
Intraocular Pressure (IOP)	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	Day 1, 1600 hours	22.76	Standard Deviation 3.558	mmHg
Intraocular Pressure (IOP)	Latanoprost Ophthalmic Solution 0.005%	Day 1, 1600 hours	22.59	Standard Deviation 3.451	mmHg
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution	Day 15, 0800 hours	16.06	Standard Deviation 3.370	mmHg

1 to 10 of 36Source ClinicalTrials.gov

See all 36 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	PG324 Ophthalmic Solution 0.02%/0.005%	245
Overall Study	STARTED	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	255
Overall Study	STARTED	Latanoprost Ophthalmic Solution 0.005%	250
Overall Study	COMPLETED	PG324 Ophthalmic Solution 0.02%/0.005%	221
Overall Study	COMPLETED	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	228
Overall Study	COMPLETED	Latanoprost Ophthalmic Solution 0.005%	236
Overall Study	NOT COMPLETED	PG324 Ophthalmic Solution 0.02%/0.005%	24
Overall Study	NOT COMPLETED	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	27
Overall Study	NOT COMPLETED	Latanoprost Ophthalmic Solution 0.005%	14

Source ClinicalTrials.gov

Adverse events57

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Conjunctival Hyperaemia	Eye disorders	PG324 Ophthalmic Solution	126	244	126
other	Conjunctival Hyperaemia	Eye disorders	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	102	255	102
other	Conjunctival Hyperaemia	Eye disorders	Latanoprost Ophthalmic Solution 0.005%	51	251	51
other	Cornea Verticillata	Eye disorders	PG324 Ophthalmic Solution	32	244	32
other	Cornea Verticillata	Eye disorders	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	25	255	25
other	Cornea Verticillata	Eye disorders	Latanoprost Ophthalmic Solution 0.005%	0	251	0
other	Conjunctival Haemorrhage	Eye disorders	PG324 Ophthalmic Solution	14	244	14
other	Conjunctival Haemorrhage	Eye disorders	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	17	255	17
other	Conjunctival Haemorrhage	Eye disorders	Latanoprost Ophthalmic Solution 0.005%	2	251	2
other	Corneal Disorder	Eye disorders	PG324 Ophthalmic Solution	14	244	14

1 to 10 of 57Source ClinicalTrials.gov

See all 57 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	PG324 Ophthalmic Solution	0	244
Total, all-cause mortality	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	1	255
Total, all-cause mortality	Latanoprost Ophthalmic Solution 0.005%	0	251
Total, other adverse events	PG324 Ophthalmic Solution	157	244
Total, other adverse events	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	143	255
Total, other adverse events	Latanoprost Ophthalmic Solution 0.005%	78	251
Total, serious adverse events	PG324 Ophthalmic Solution	2	244
Total, serious adverse events	Netarsudil (AR-13324) Ophthalmic Solution 0.02%	6	255
Total, serious adverse events	Latanoprost Ophthalmic Solution 0.005%	5	251

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
31981106	DERIVED	PubMed
32166538	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02674854

GET https://conductscience.org/api/trials/v1/NCT02674854/results?page=2

API reference For AI assistants